To investigate the impact of dapagliflozin, one of the SGLT2 inhibitors, on the liver, Furuya et al. performed in vivo experiments followed by a small clinical study among hospitalized patients with T2D (n = 12) [96]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.